Desjardins, A., Vredenburgh, J. J., Reardon, D. A., Herndon, J. E., Marcello, J., Peters, K., … Friedman, H. S. (2010). Long-term survival from the initial trial of bevacizumab and irinotecan. JOURNAL OF CLINICAL ONCOLOGY, 28(15).

Desjardins, A., J. J. Vredenburgh, D. A. Reardon, J. E. Herndon, J. Marcello, K. Peters, S. Gururangan, S. Sathornsumetee, J. N. Rich, and H. S. Friedman. “Long-term survival from the initial trial of bevacizumab and irinotecan.” JOURNAL OF CLINICAL ONCOLOGY 28, no. 15 (May 20, 2010).

Desjardins A, Vredenburgh JJ, Reardon DA, Herndon JE, Marcello J, Peters K, et al. Long-term survival from the initial trial of bevacizumab and irinotecan. JOURNAL OF CLINICAL ONCOLOGY. 2010 May 20;28(15).

Desjardins, A., et al. “Long-term survival from the initial trial of bevacizumab and irinotecan.” JOURNAL OF CLINICAL ONCOLOGY, vol. 28, no. 15, AMER SOC CLINICAL ONCOLOGY, May 2010.

Desjardins A, Vredenburgh JJ, Reardon DA, Herndon JE, Marcello J, Peters K, Gururangan S, Sathornsumetee S, Rich JN, Friedman HS. Long-term survival from the initial trial of bevacizumab and irinotecan. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2010 May 20;28(15).